Annual SGA
$168.01 M
+$38.58 M+29.81%
December 31, 2024
Summary
- As of March 1, 2025, KNSA annual SGA is $168.01 million, with the most recent change of +$38.58 million (+29.81%) on December 31, 2024.
- During the last 3 years, KNSA annual SGA has risen by +$82.06 million (+95.48%).
- KNSA annual SGA is now at all-time high.
Performance
KNSA SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly SGA
$40.53 M
-$5.86 M-12.64%
December 31, 2024
Summary
- As of March 1, 2025, KNSA quarterly SGA is $40.53 million, with the most recent change of -$5.86 million (-12.64%) on December 31, 2024.
- Over the past year, KNSA quarterly SGA has dropped by -$5.86 million (-12.64%).
- KNSA quarterly SGA is now -12.64% below its all-time high of $46.40 million, reached on September 30, 2024.
Performance
KNSA Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM SGA
-$2.03 B
-$43.19 M-2.18%
December 31, 2024
Summary
- As of March 1, 2025, KNSA TTM SGA is -$2.03 billion, with the most recent change of -$43.19 million (-2.18%) on December 31, 2024.
- Over the past year, KNSA TTM SGA has dropped by -$2.19 billion (-1335.34%).
- KNSA TTM SGA is now -2129.30% below its all-time high of -$91.00 million.
Performance
KNSA TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
KNSA Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +29.8% | -12.6% | -1335.3% |
| 3 y3 years | +95.5% | +78.3% | -2460.3% |
| 5 y5 years | +380.6% | +318.1% | -5902.3% |
KNSA Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +95.5% | -12.6% | +82.4% | -3.2% | +25.9% |
| 5 y | 5-year | at high | +380.6% | -12.6% | +377.7% | -63.9% | +25.9% |
| alltime | all time | at high | +2460.0% | -12.6% | +2030.1% | -2129.3% | +25.9% |
Kiniksa Pharmaceuticals Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $168.01 M(+29.8%) | $40.53 M(-12.6%) | $168.01 M(+2.3%) |
| Sep 2024 | - | $46.40 M(+9.4%) | $164.22 M(+7.8%) |
| Jun 2024 | - | $42.40 M(+9.6%) | $152.28 M(+9.5%) |
| Mar 2024 | - | $38.68 M(+5.3%) | $139.06 M(+7.4%) |
| Dec 2023 | $129.43 M(+32.1%) | $36.74 M(+6.6%) | $129.43 M(+7.9%) |
| Sep 2023 | - | $34.47 M(+18.1%) | $119.90 M(+8.9%) |
| Jun 2023 | - | $29.18 M(+0.4%) | $110.11 M(+5.1%) |
| Mar 2023 | - | $29.05 M(+6.7%) | $104.78 M(+7.0%) |
| Dec 2022 | $97.95 M(+14.0%) | $27.21 M(+10.3%) | $97.95 M(+4.8%) |
| Sep 2022 | - | $24.68 M(+3.5%) | $93.48 M(+4.4%) |
| Jun 2022 | - | $23.84 M(+7.3%) | $89.56 M(+2.3%) |
| Mar 2022 | - | $22.22 M(-2.3%) | $87.57 M(+1.9%) |
| Dec 2021 | $85.95 M(+89.6%) | $22.74 M(+9.5%) | $85.95 M(+9.2%) |
| Sep 2021 | - | $20.76 M(-5.0%) | $78.71 M(+12.8%) |
| Jun 2021 | - | $21.85 M(+6.1%) | $69.75 M(+21.4%) |
| Mar 2021 | - | $20.60 M(+32.9%) | $57.44 M(+26.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2020 | $45.32 M(+29.6%) | $15.50 M(+31.4%) | $45.32 M(+14.7%) |
| Sep 2020 | - | $11.80 M(+23.7%) | $39.52 M(+9.3%) |
| Jun 2020 | - | $9.54 M(+12.4%) | $36.15 M(+3.1%) |
| Mar 2020 | - | $8.49 M(-12.5%) | $35.05 M(+0.3%) |
| Dec 2019 | $34.96 M(+62.1%) | $9.70 M(+15.0%) | $34.96 M(+5.1%) |
| Sep 2019 | - | $8.43 M(-0.1%) | $33.28 M(+9.6%) |
| Jun 2019 | - | $8.44 M(+0.6%) | $30.36 M(+15.7%) |
| Mar 2019 | - | $8.39 M(+4.8%) | $26.25 M(+21.7%) |
| Dec 2018 | $21.56 M(+138.4%) | $8.01 M(+45.3%) | $21.57 M(+32.0%) |
| Sep 2018 | - | $5.51 M(+27.5%) | $16.33 M(+25.1%) |
| Jun 2018 | - | $4.33 M(+16.6%) | $13.06 M(+20.3%) |
| Mar 2018 | - | $3.71 M(+33.5%) | $10.85 M(+20.0%) |
| Dec 2017 | $9.04 M(+37.8%) | $2.78 M(+24.1%) | $9.04 M(+44.4%) |
| Sep 2017 | - | $2.24 M(+5.7%) | $6.26 M(+55.7%) |
| Jun 2017 | - | $2.12 M(+11.4%) | $4.02 M(+111.4%) |
| Mar 2017 | - | $1.90 M | $1.90 M |
| Dec 2016 | $6.56 M | - | - |
FAQ
- What is Kiniksa Pharmaceuticals annual SGA?
- What is the all time high annual SGA for Kiniksa Pharmaceuticals?
- What is Kiniksa Pharmaceuticals annual SGA year-on-year change?
- What is Kiniksa Pharmaceuticals quarterly SGA?
- What is the all time high quarterly SGA for Kiniksa Pharmaceuticals?
- What is Kiniksa Pharmaceuticals quarterly SGA year-on-year change?
- What is Kiniksa Pharmaceuticals TTM SGA?
- What is the all time high TTM SGA for Kiniksa Pharmaceuticals?
- What is Kiniksa Pharmaceuticals TTM SGA year-on-year change?
What is Kiniksa Pharmaceuticals annual SGA?
The current annual SGA of KNSA is $168.01 M
What is the all time high annual SGA for Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals all-time high annual SGA is $168.01 M
What is Kiniksa Pharmaceuticals annual SGA year-on-year change?
Over the past year, KNSA annual SGA has changed by +$38.58 M (+29.81%)
What is Kiniksa Pharmaceuticals quarterly SGA?
The current quarterly SGA of KNSA is $40.53 M
What is the all time high quarterly SGA for Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals all-time high quarterly SGA is $46.40 M
What is Kiniksa Pharmaceuticals quarterly SGA year-on-year change?
Over the past year, KNSA quarterly SGA has changed by -$5.86 M (-12.64%)
What is Kiniksa Pharmaceuticals TTM SGA?
The current TTM SGA of KNSA is -$2.03 B
What is the all time high TTM SGA for Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals all-time high TTM SGA is -$91.00 M
What is Kiniksa Pharmaceuticals TTM SGA year-on-year change?
Over the past year, KNSA TTM SGA has changed by -$2.19 B (-1335.34%)